The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...
A novel transcatheter-implanted system that shunts blood flow from the left to right atrium through the coronary sinus has ...
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Patients with progressive pulmonary fibrosis who received nerandomilast showed improved forced vital capacity from baseline ...
A new, generic, non-steroidal anti-inflammatory drug (NSAID) is now available for managing osteoarthritis (OA) pain in horses ...
Adults with progressive pulmonary fibrosis met the primary endpoint of absolute change in FVC with 52-week oral nerandomilast ...
Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.
Boehringer Ingelheim has cemented the potential of its idiopathic pulmonary fibrosis (IPF) drug with a second phase 3 win in ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback